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Background: Resistance to sulphadoxine-pyrimethamine (SP) in Plasmodium falciparum parasites is associated with
mutations in the dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes and has spread worldwide.
SP remains the recommended drug for intermittent preventive treatment for malaria in pregnancy (IPTp) and
information on population prevalence of the SP resistance molecular markers in pregnant women is limited.
Methods: Temporal trends of SP resistance molecular markers were investigated in 489 parasite samples collected from
pregnant women at delivery from three different observational studies between 1996 and 2009 in Kenya, where SP was
adopted for both IPTp and case treatment policies in 1998. Using real-time polymerase chain reaction, pyrosequencing
and direct sequencing, 10 single-nucleotide polymorphisms (SNPs) of SP resistance molecular markers were assayed.
Results: The prevalence of quintuple mutant (dhfr N51I/C59R/S108N and dhps A437G/K540E combined genotype)
increased from 7 % in the first study (1996–2000) to 88 % in the third study (2008–2009). When further stratified by
sample collection year and adoption of IPTp policy, the prevalence of the quintuple mutant increased from 2.4 % in
1998 to 44.4 % three years after IPTp policy adoption, seemingly in parallel with the increase in percentage of SP use in
pregnancy. However, in the 1996–2000 study, more mutations in the combined dhfr/dhps genotype were associated
with SP use during pregnancy only in univariable analysis and no associations were detected in the 2002–2008 and
2008–2009 studies. In addition, in the 2008–2009 study, 5.3 % of the parasite samples carried the dhps triple mutant
(A437G/K540E/A581G). There were no differences in the prevalence of SP mutant genotypes between the parasite
samples from HIV + and HIV- women over time and between paired peripheral and placental samples.
Conclusions: There was a significant increase in dhfr/dhps quintuple mutant and the emergence of new genotype
containing dhps 581 in the parasites from pregnant women in western Kenya over 13 years. IPTp adoption and SP use
in pregnancy only played a minor role in the increased drug-resistant parasites in the pregnant women over time. Most
likely, other major factors, such as the high prevalence of resistant parasites selected by the use of SP for case
management in large non-pregnant population, might have contributed to the temporally increased prevalence of SP
resistant parasites in pregnant women. Further investigations are needed to determine the linkage between SP drug
resistance markers and efficacy of IPTp-SP.
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Malaria during pregnancy persists as a major public health
challenge with adverse consequences for the pregnant
woman and the developing foetus. About 50 million women
living in malaria-endemic countries become pregnant each
year [1]. In Africa, an estimated 30 million women are at
risk of Plasmodium falciparum infection during pregnancy
annually [2]. Human immunodeficiency virus (HIV) and
malaria have overlapping global distributions [3]. Currently,
available interventions to prevent or mitigate the adverse
effects of malaria during pregnancy include intermittent
preventive treatment in pregnancy (IPTp), insecticide-
treated bed-nets (ITNs), and case management. In sub-
Saharan Africa, the World Health Organization (WHO)
recommends the administration of at least two curative
doses of sulphadoxine-pyrimethamine (SP) for IPTp after
the first trimester of pregnancy [4]. A recent study indi-
cated that three doses of SP are required to provide ad-
equate protection to pregnant women [5]. More SP doses
are also recommended for women with HIV who are not
taking daily cotrimoxazole (CTX, sulphamethoxazole-
trimethoprim) for the prevention of opportunistic infec-
tions [4]. However, for HIV-infected women taking CTX,
WHO does not recommend IPTp-SP, as CTX inhibits the
same enzymes as SP in the folic acid biosynthetic pathway,
presumably acting as an anti-malarial, and the excess of
adverse events were observed in the SP and CTX co-
medication [4].
In most African countries, SP remains the recommended
drug for IPTp due to its safety profile, efficacy, cost effect-
iveness and easy administration through the existing health
structures, such as antenatal clinics (ANC) [6,7]. IPTp-SP
has been shown to reduce the prevalence of placental mal-
aria infection, maternal severe anaemia in primigravidae
[8-12], preterm delivery [5,13], infant low birth-weight
[5,13-15] and the neonatal mortality rate [16]. However,
P. falciparum resistance to SP has emerged, originating at
the Thailand-Cambodia border and then spreading rapidly
to other Asian countries and subsequently to Africa [17].
Concurrently, cross-resistance has also developed between
trimethoprim and pyrimethamine in P. falciparum malaria
parasites [18]. Due to the increasing SP and existing high
chloroquine resistance, WHO has recommended artemisi-
nin-based combination therapy (ACT) as alternative first-
line treatment for uncomplicated malaria in most endemic
countries. However, ACT is not recommended for preven-
tion of malaria including in pregnant women due to the
absence of adequate safety data [19].
Resistance to SP has been linked to point mutations in
the parasite dihydrofolate reductase (dhfr) and dihy-
dropteroate synthase (dhps) genes [20,21]. Mutations in
dhfr confer resistance to pyrimethamine, which occurs
in a stepwise pattern [22], while mutations in dhps con-
fer resistance to sulphadoxine and other sulpha drugs.In sub-Saharan Africa, the dhfr triple mutant (Asn-
108/Ile-51/Arg-59) and dhps double mutant (Gly-437/
Glu-540) have been strongly associated with resistance
to SP while the Leu-164 mutation, a major contribu-
tor to the rapid spread of high level anti-folate resist-
ance, has recently begun to emerge in Africa [23-25].
The dhps mutation at codon 581 is linked with a high
rate of therapeutic failure and the emergence of the
dhps triple mutant allele (A437G/K540E/A581G) has
been confirmed in Tanzania [26], and the prevalence
is increasing [27]. Recently, the dhps mutation at posi-
tions 581 and 613 were reported in Kenya [28]. Collect-
ively, these data confirm that the quintuple mutant,
comprised of the dhfr triple mutant (Asn-108/Ile-51/Arg-
59) genotype and dhps double mutant (Gly-437/Glu-540)
genotype, and other additional dhfr and dhps mutations
are good predictors of SP treatment failure in children
[25,29-31].
The rapid spread of SP-resistant parasites associated
with SP treatment failure in children [31] and paucity of
scientific data linking SP resistant parasites and IPTp-SP
efficacy in pregnant women [32] highlights the need for
an evaluation of the prevalence of SP molecular markers
in the context of IPTp-SP. Recently, studies conducted
in Tanzania (data and samples from 2002–2005) showed
that IPTp-SP was associated with an increased fraction
of parasites carrying the resistant allele at dhps 581, an
increased parasite density and intense placental inflam-
mation [33], and further suggested that IPTp may not
improve overall pregnancy outcomes [34]. However, IPTp-
SP was effective in preventing placental malaria infection
in several subsequent studies conducted in other African
countries [5,13,35]. Another recent report showed that
IPTp-SP increased the prevalence of dhfr/dhps quintuple
mutant infection in HIV-infected pregnant women, but
the women with drug-resistant parasites did not have
increased malaria-related adverse clinical outcomes [36].
The results from these divergent studies suggest that
although IPTp-SP could select resistant parasites, IPTp-SP
remains beneficial in its protection against malaria infec-
tion in some African countries [5,13,35].
This study was conducted using the parasites from
Kenyan pregnant women to (a) determine the temporal
trends of SP resistance molecular markers over 13 years
(between 1996 and 2009), (b) assess if there are any not-
able differences between peripheral and placental para-
sites in the profile of SP resistance molecular markers,
and (c) examine the relationship between SP resistance
molecular markers and IPTp adoption and use of SP
during pregnancy, further stratified by HIV status. The
study was conducted in the malaria endemic area of
western Kenya where there is a high prevalence of HIV
co-infection and IPTp-SP policy and SP treatment policy
were both adopted in 1998.
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Study sites and sample sources
This study used the samples collected from three separate
hospital-based malaria in pregnancy studies conducted in
Nyanza province, western Kenya between 1996 and 2009.
Details for these three observational studies have been
described elsewhere ([37,38] and Ouma et al, manuscript
in preparation). Briefly, between 1996 and 2000, a malaria
in pregnancy study was conducted in Provincial General
Hospital, Kisumu town to assess the effect of placental
malaria on perinatal HIV infection. A second malaria in
pregnancy immunological study designed to investigate
cellular immune responses in pregnant women was carried
out at the same hospital from 2002 to the middle of 2004
and then continued at Siaya District Hospital until 2008. A
third malaria in pregnancy study was conducted between
2008 and 2009 in both Siaya and Bondo District Hospitals
and the aim of this study was to assess the effectiveness of
daily IPTp with SP or CTX prophylaxis in preventing
placental malaria in pregnant women. Both Siaya and
Bondo District Hospitals are located in rural areas around
Kisumu town. Compared to Kisumu town, the rural areas
have a relatively higher malaria transmission. The first two
studies collected the history of self-reported SP use (case
management or any dose of IPTp) during pregnancy while
the 2008–2009 study obtained information for both IPTp-
SP use and CTX use validated by antenatal clinic records.
In Kenya, although the policy of IPTp-SP was adopted in
1998 and it remains till now as per Kenya Ministry of
Health (MOH) guidelines, uptake was slow, evidenced by
the study showing only 7 % of pregnant women received
more than one dose of SP in western Kenya 4 years after
the adoption of IPTp-SP policy [39]. Daily CTX prophy-
laxis for the prevention of opportunistic infections in
pregnant women was officially recommended as one
component of HIV care in 2005 and the distribution of
free ITNs to pregnant women became part of antenatal
care in early 2008. In addition, although the drug policy
in Kenya shifted to SP from chloroquine in 1998 and
then to CoartemW in 2004 for the treatment of uncom-
plicated malaria, as late as 2010, SP was still used to
treat uncomplicated malaria in 37 % of households sur-
veyed in Kisumu, compared to 32 % that used ACT [40].
The prevalence of the dhfr/dhps quintuple mutant in
children from the same study area increased from 29 %
in 1996 to 62 % and 85 % in 2001 and 2007, respectively
[41].
For all three observational studies described above, sam-
ples were collected at delivery. The selection of samples
from the three studies for the present investigation was
based on the availability of samples in both HIV+ and
HIV- women rather than randomization of characteristics.
In total, 489 peripheral samples from patients who were
P. falciparum parasite positive at delivery were used forthe study: 180 from 1996–2000, 176 from 2002–2008 and
133 from 2008–2009. In addition, among the 133 periph-
eral samples from the 2008–2009 period, 125 were paired
with placental samples from the same woman.
This study was approved by the Institutional Review
Board of the Kenya Medical Research Institute (KEMRI)
Nairobi, Kenya, the University of Georgia, Athens, USA,
and the Centers for Disease Control and Prevention (CDC)
Atlanta, Georgia, USA. Written informed consent was
obtained from all study participants.
Laboratory procedures
DNA purification
Genomic DNA was purified from dried blood spots col-
lected from the 2008–2009 period using the Chelex
method [42] and also from frozen red blood cell pellets
for the remaining samples by micro-centrifugation using
a commercial DNA purification QIAampW blood mini-
kit (Qiagen Inc., CA, USA).
Single nucleotide polymorphisms genotyping
Ten single nucleotide polymorphisms (SNPs) at dhfr codons
50, 51, 59, 108 and 164, and dhps codons 436, 437, 540, 581
and 613 were typed using real-time polymerase chain reac-
tion (RT-PCR), pyrosequencing and direct sequencing.
RT-PCR
RT-PCR (Stratagene Mx3005P, CA, USA) was used to
detect SNPs at dhfr codons 51, 59, 108, 164 and dhps
codons 437 and 540 for 2008–2009 samples using a pub-
lished procedure [43]. Briefly, standards and field sam-
ples were run in duplicate in 25 μl reactions containing
TaqMan Universal Mastermix (Applied Biosystems, CA,
USA), 2 μl of DNA (diluted 1:10), gene-specific forward
and reverse primers, and SNP-specific TaqMan MGB
probes (Applied Biosystems, CA, USA). Four 10-fold serial
dilutions of both wild type and mutant parasite laboratory
strain standards, depending on the SNP, and negative con-
trol templates were run on every plate as positive and
negative controls.
PCR for pyrosequencing and pyrosequencing reactions
The remaining SNPs for 2008–2009 samples and all the
SNPs for 1996–2000 and 2002–2008 samples were assayed
using a published pyrosequencing method [44]. All PCR
primers and sequence primers were synthesized at the
CDC Biotechnology Core Facility, Atlanta, USA and ex-
periment conditions were followed based on the described
procedures [44]. The following laboratory strains were
used as controls for detecting wild and mutant strains:
3D7 (wild type) for dhfr 50, 51, 59, 108, 164 and dhps 436,
581, 613; Dd2 (mutant) for dhfr 50, 51, 59 and dhps 613;
V1/S (mutant) for dhfr 108, 164 and dhps 613; FCR3 (wild
type) for dhps 437; D6 (mutant) for dhps 436; 3D7
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(mutant) for dhps 540; and K1 (mutant) for dhps 581. No
DNA templates were included in all reactions as negative
controls. The assays were performed on the PSQ 96 plate
using PyroMark ID (Biotage AB, Uppsala, Sweden) and
the sample genotypes were determined using the Pyro-
Mark ID 1.0 SNP software (Biotage AB).
Direct sequencing
All moot results and new mutations were confirmed by
direct sequencing. Dhfr and dhps fragments were ampli-
fied using nested PCR sequence protocols [45]. Sequen-
cing of the nested purified PCR products were performed
using Big Dye Terminator v3.1 cycle sequencing kit on
iCycler thermal cycler (Bio-Rad). The reactions were preci-
pitated in 70 % ethanol to clean up dye terminators, rehy-
drated in 10 ml HiDi formamide and then sequenced on a
3130 ABI Genetic Analyzer (ABI Prism, CA, USA).
Genotyping for multiplicity of infection
Size variant alleles of merozoite surface protein 1 (msp1)
and msp2 were determined by nested PCR for the assess-
ment of multiplicity of infection (MOI). The sequences
of the oligonucleotide primers used for amplification of
the genetic markers and experimental conditions were
set based on the published and recommended methods
[46,47]. Positive and negative controls were included in
each experiment. The nested PCR products were ana-
lysed by 3 % agarose gel electrophoresis and visualized
by ultraviolet transilluminator after staining with ethidium
bromide. The band sizes were estimated using the gel
imaging system and the Labworks image acquisition and
analysis software v4.6 (UVP BioImaging Systems, CA,
USA).
Definitions
Drug-resistant markers
For all 10 SNPs genotyped, each was coded to designate
pure (infection with only either wild type or mutant
strains) or mixed (infection with both wild and mutant
strains where the minor strain was >30 % of major).
Mixed infection was considered as mutant. The SP gen-
otypes (dhfr, dhps and combined dhfr/dhps) were cate-
gorized based on the criteria of Kublin et al [29]. Dhfr
genotype, based on mutations at codons 51, 59, and 108,
was classified as wild type, single, double, and triple
(pooled triple mixed and pure) while dhps genotype
(mutations at codons 437 and 540) was classified as wild
type, single, and double (pooled double mixed and pure).
Combined dhfr and dhps genotypes (mutations at dhfr
51, 59, 108 + dhps 437, 540) were defined as wild type,
single, double, triple, quadruple, quintuple (pooled quin-
tuple mixed and pure). The quadruple mutants were
categorised either as dhfr triple + dhps single or dhfrdouble + dhps double. The quintuple mutants, in either
pure or mixed infection, represent infections in which
all the five mutations were detected at codons 51, 59,
108, 437 and 540. Furthermore, additional combinations
of dhps SNPs at codons 436, 437 and 540, at codons
437, 540 and 581, or at codons 436, 437, 540 and 581
were analysed to further evaluate the progression of dhps
mutations. In this study, the prevalence of SNP mutations
and genotypes were estimated [29].
Multiplicity of infection
MOI was assessed by using the polymorphic regions of
P. falciparum msp1 and msp2 genes as markers. Since
the size variant alleles of msp2 was consistently more
diverse than msp1 in previous studies [46,48] and in the
current study, msp2 was selected to evaluate MOI. Mean
MOI was calculated as the total number of variant alleles
(clones) divided by the number of positive samples for the
marker gene msp2. Mixed infection was defined as individ-
ual infection with more than one variant allele (clone).
Clinical
As there were differences in the collection of data for SP
use in pregnancy for the three different observational
studies, the common variable “SP use in pregnancy (yes
or no)” was used which represented the history of self-
reported SP use by either case management or any dose
of IPTp-SP for first two study periods and validated
IPTp-SP use for the third study period. Other variables
used in analysis included adoption of IPTp policy (yes or
no, policy adopted in 1998), Cotrimoxazole use (yes or
no, data only collected in third study), maternal age,
gravidity (categorized as primigravid, secundigravid, and
multigravid), area of residence, haemoglobin level (g/dl)
at delivery (<11 g/dl considered anaemic), peripheral and
placental parasite density (parasites/μl) determined by
standard microscopic examination of blood smears, and
confirmed HIV status by standard laboratory serological
tests using same algorithm.
Data and statistical analysis
The objectives of the present study were to determine
the prevalence of SP molecular markers in the parasites
from pregnant women over time from 1996 to 2009 and
to explore potential epidemiological factors affecting the
prevalence of SP resistance molecular markers in the
pregnant women. Therefore, the analysis strategies included:
1) a descriptive analysis on temporal trend of drug resistant
markers, mixed infection and MOI, and comparisons of
these parameters between peripheral and placental samples
and between HIV statuses of samples used, and 2) an associ-
ation analysis between mutations in resistance genotypes as
the outcome variables and use of SP in pregnancy as the
primary exposure variable.
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different studies were analysed by Pearson chi-square
tests and ANOVA. Parasite density was log transformed
prior to statistical analysis. Differences in the prevalence
of SNP mutations, dhfr, dhps and the combined dhfr/dhps
genotypes among the three studies and other subcompo-
nent comparisons were examined by overall chi-square
tests or exact chi-square tests for expected cell counts less
than five, considering each molecular marker or genotype
as independent. The details of the descriptive analysis are
described in additional file [see Additional file 1].
To examine the relationship between SP use in preg-
nancy and dhfr, dhps, and combined dhfr/dhps geno-
types, univariable and multivariable logistic regression
analyses were performed. As the original study method-
ologies differed, data from the three studies were not
pooled, but instead, analysed separately. In all epidemio-
logical models, SP use in pregnancy was considered the
primary exposure of interest and the (1) dhfr (N51I/
C59R/S108N), (2) dhps (A437G/K540E), or (3) combined
dhfr/dhps genotypes as three separate outcomes. The final
most parsimonious multivariable model in each study was
selected after an assessment of regression assumptions,
interaction and confounding factors. No interaction terms
were included in any final models as all possible two-way
interaction terms with the primary exposure of interest
were insignificant at the α=0.05 significance level based
on an overall likelihood ratio test. Confounding was
assessed based on a +/− 10 % change in odds ratio (OR)
estimate, biological plausibility and the results of univari-
able analysis. Placental parasite density and maternal age
were excluded from the final models due to co-linearity
with peripheral parasite density and gravidity, respectively.
For the 2008–2009 study, CTX use was excluded from the
final model due to expected co-linearity with HIV, as CTX
is administered to HIV positive women. The final models
derived for all three outcomes and for all three studies
contained the variables: use of SP in pregnancy, maternal
haemoglobin level at delivery, gravidity, logarithmic per-
ipheral parasite density, HIV status, sample collection year,
area of residence and number of msp2 clones. Given the
different distributions of outcome genotype profiles for
each study period, binary or cumulative logistic regressions
were performed for each study separately. The proportional
odds assumption was evaluated for cumulative logistic re-
gression models using the score test, where P< 0.05
reflected a violation of the assumption. In addition, to en-
sure sufficient sample size in each category for analysis,
some genotype categories were collapsed in both binary
and cumulative logistic regression. The genotype outcome
categories and logistic regression models used for each
study period are described in detail in additional file [see
Additional file 1]. All statistical tests were two-tailed and
statistical significance was defined as P< 0.05. Data analysiswas performed with IBM SPSS Statistics version 17.0 (SPSS
Inc., IL, USA) and SAS version 9.2 (SAS Inc., NC, USA).
Results
Characteristics of the study participants
Clinical characteristics
Table 1 describes the characteristics of the pregnant women
whose P. falciparum parasite positive samples were used
in the current study. Use of SP in pregnancy among the
participants differed significantly in the three study periods
(P< 0.001), with an overall increase from 9.4 % in 1996–
2000 study to 67.7 % in 2008–2009 study. In the 2008–
2009 study, 23 % of the falciparum malaria parasite posi-
tive participants took CTX. There was a difference in mean
age but no difference in the parity distribution among the
three different studies and, for all three studies, primigravid
women were predominant. Parasite density in the placenta
was higher than in the periphery. Although there was no
statistical difference in both peripheral and placental para-
site density among the study periods, there was higher pla-
cental parasite density in the samples from 2008–2009
compared to those from 1996–2000 (P=0.034). More than
half of the pregnant women, irrespective of the study
period, were anaemic at delivery. In addition, there was a
difference in the proportion of HIV sero-positive samples
that were used in this study, with a greater proportion of
HIV positive samples used in 1996–2000 compared to in
2008–2009.
Prevalence of SNP mutations
Mutated amino acids and genetic codes are shown in
bold font in Table 1. No mutations were detected at dhfr
50 and dhps 613 in any study period. However, the muta-
tion at dhfr 164 was detected only in one sample each in
2002–2008 (0.6 %) and in 2008–2009 (0.8 %). In addition,
the mutation at dhps position 581 was not detected prior
to 2008, but was found in 5.3 % of the 2008–2009 samples.
The prevalence of dhps 436 mutations including S436A,
S436F, and S436H was 11.7 %, 2.8 % and 6.1 % for the
three studies, respectively, among which the new 436 mu-
tation, S436H, was detected in 2.3 % of 2002–2008 and
3.8 % of 2008–2009 samples. Overall, the prevalence of
SNP mutations in dhfr 51, 59, 108 and dhps 437, 540 dif-
fered significantly among the three studies (P< 0.031), no-
ticeably increasing from 78.9 % to 97.7 % (N51I), 51.7 % to
90.2 % (C59R), 97.8 % to 100 % (S108N), 42.8 % to 100 %
(A437G) and 31.1 % to 99.2 % (K540E), respectively from
1996–2000 to 2008–2009 (Table 1).
Comparison of the prevalence of SP resistance markers,
mean MOI and the number of clones between peripheral
and placental samples
In order to assess if there were any notable differences
between peripheral and placental parasites, SP-resistant
Table 1 Characteristics of pregnant women who were Plasmodium falciparum positive by study period
Characteristics 1996-2000 2002-2008 2008-2009 P valuea
n=180 (%) n= 176 (%) n=133 (%)
Use of SP in pregnancyb
Yes
No 17 (9.4) 90 (53.6) 90 (67.7) <0.001
163 (90.6) 78 (46.4) 43 (32.3)
Septrin/Cotrimoxazole use
Yes - - 32 (23.1) -
No - - 101 (75.9)
Mother’s age
Mean± SD (years) 20.4 ± 4.1 21.1 ± 4.5 22.3 ± 5.3 0.002
Gravidity
Primigravid 104 (57.8) 90 (51.1) 72 (54.1)
Secundigravid 40 (22.2) 41 (23.3) 25 (18.8) 0.50
Multigravid 36 (20.0) 45 (25.6) 36 (27.1)
Placental malaria (parasites/μl)
Geometric mean 1688.3* 2212.8 3006.5* 0.10
(95 % CI) (1220.01 to 2336.2) (1558.2 to 3142.4) (1946 to 4644.7)
Peripheral malaria (parasites/μl)
Geometric mean 713.1 884.3 683.7 0.56
(95 % CI) (534.4 to 951.5) (597.7 to 1308.2) (463.9 to 1007.7)
Maternal anaemia at deliveryc
<11 g/dl 99 (55.9) 63 (55.3) 90 (67.7) 0.030
>11 g/dl 78 (44.1) 51 (44.7) 43 (32.3)
HIV status
HIV- 96 (53.3) 120 (68.2) 95 (70.9) 0.002
HIV+ 84 (46.7) 56 (31.8) 38 (29.1)
50
C (TGT) 180 (100) 176 (100) 132 (100) N/A
R (CGT) 0 (0) 0 (0) 0 (0)
51
N (AAT) 38 (21.1) 3 (1.7) 3 (2.3) <0.001
I (ATT) 142 (78.9) 173 (98.3) 130 (97.7)
59
C (TGT) 87 (48.3) 26 (14.8) 13 (9.8) <0.001
R (CGT) 93 (51.7) 150 (85.2) 120 (90.2)
108
S (AGC) 4 (2.2) 0 (0) 0 (0) 0.031
N (AAC) 176 (97.8) 176 (100) 133 (100)
164
I (ATA) 180 (100) 175 (99.4) 131 (99.2) 0.54
L (TTA) 0 (0) 1 (0.6) 1 (0.8)
436&
S (TCT) 159 (88.3) 171 (97.2) 124 (93.9) 0.004
A/F/H (GCT/TTT/CAT) 21 (11.7) 5 (2.8) 8 (6.1)
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Table 1 Characteristics of pregnant women who were Plasmodium falciparum positive by study period (Continued)
437
A (GCT) 103 (57.2) 4 (2.3) 0 (0) <0.001
G (GGT) 77 (42.8) 172 (97.7) 133 (100)
540
K (AAA) 124 (68.9) 6 (3.4) 1 (0.8) <0.001
E (GAA) 56 (31.1) 170 (96.6) 132 (99.2)
581
A (GCG) 180 (100) 176 (100) 124 (94.7) <0.001
G (GGG) 0 (0) 0 (0) 7 (5.3)
613
A (GCC) 178 (100) 176 (100) 133 (100) N/A
T/S (ACC/TCC) 0 (0) 0 (0) 0 (0)
Note: Data are proportion (%) of Plasmodium falciparum smear-positive samples unless otherwise indicated. Mutated amino acids and genetic codes are depicted
in bold font.
n = number of samples. CI = confidence interval. SD = Standard deviation. N/A = not applicable.
a P values based on Pearson chi-square test or exact chi-square for categorical variables and ANOVA for comparison of the mean of continuous variables.
b For 1996–2000 and 2002–2008 (n = 168) studies, only history of SP use (case management or any dose of IPTp-SP) in pregnancy was documented while IPTp use
was recorded for 2008–2009.
c For 1996–2000 (n = 177), 2002–2008 (n = 114).
*Placental parasite density comparison between 1996–2000 and 2008–2009 (P = 0.034).
&S436H, the new mutation at codon 436, was detected at 2.3 % in 2002–2008 and 3.8 % in 2008–2009.
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of clones were compared in the peripheral and placental-
paired samples from the 2008–2009 study period. There
was no significant difference in the prevalence of the com-
bined dhfr/dhps genotype in the peripheral and placental-
paired samples (P= 0.54) (Figure 1A). In the analysis of
mean MOI, the difference between periphery (1.11 ± 0.79)
and placenta (1.32 ± 0.94) was not significant (P= 0.20).
The number of distinguishable P. falciparum clones defined
by msp2 variant alleles ranged between one and four. No
differences in the distribution of number of clones were
found in the peripheral and placental-paired samples
(P=0.19) (Figure 1B).
Temporal trends of dhfr, dhps and the combined dhfr/
dhps genotypes
Figure 2 shows the temporal trends by the three study
periods. The prevalence of the dhfr triple mutant (N51I/
C59R/S108N) increased considerably from 27 % in 1996–
2000 to 89 % in 2008–2009 and was significantly different
across studies (P< 0.001), while the dhps double mutant
(A437G/K540E) also increased from 27 % to 99 % and also
differed significantly among studies (P< 0.001) [Figure 2A,
B, respectively]. Figure 2C shows the temporal trends of
the combined dhfr and dhps genotypes, based on the
mutations at dhfr 51, 59, 108 and dhps 437, 540 classified
as wild type, single, double, triple, quadruple, and quintu-
ple. The prevalence of the quintuple mutant differed in the
three studies (P< 0.001), increasing from 7 % in 1996–
2000 to 88 % in 2008–2009. However, in all three studies,there were no statistically significant differences in the
prevalence of dhfr, dhps and the combined dhfr/dhps gen-
otypes between the parasites samples from HIV+and
HIV- women (see Additional file 2a, b, and c, respectively).
As the number of years for the three studies varied,
particularly the wide range of years (2002–2008) for the
second study, the prevalence data was further stratified
by years and IPTp policy adoption (Figure 3). The preva-
lence of dhfr triple, dhps double and the combined dhfr/
dhps quintuple mutants increased from 22.8 %, 19.5 %
and 2.4 % in 1998 to 63.9 % (P< 0.001), 69.4 % (P< 0.001)
and 44.4 % (P< 0.001), respectively, about three years after
IPTp policy adoption (Figure 3). Subsequently, the preva-
lence of the drug-resistant molecular markers steadily
increased, and by year 2009, the prevalence of the corre-
sponding drug resistance mutant genotypes reached more
than 90 % in the study population. In addition, Figure 3
shows that the percentage of participants who used SP
during pregnancy after IPTp policy adoption seemingly
parallels with the temporal trend for prevalence of drug re-
sistant genotypes.
Table 2 shows the temporal change of three additional
dhps combinations from 1996 to 2009. The dhps triple
mutant which consists of the combination of mutations at
dhps 436, 437 and 540 was not observed in the first study
period but increased from 2.3 % in 2002–2008 study to
6 % in 2008–2009 study. In addition, the dhps triple mu-
tant comprising of the combination of mutations at dhps
437, 540, and 581 was only detected at 5.3 % in 2008–
2009 study. Furthermore, the combination of quadruple
Figure 1 Comparison of molecular profiles between paired peripheral and placental samples in 2008–2009 study period. A, combined
dhfr/dhps genotypes. B, proportion of the number of clones (msp2).
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http://www.malariajournal.com/content/11/1/134mutations at dhps 436, 437, 540 and 581, not previously
detected in Kenya prior to 2008, showed a prevalence of
0.8 % in 2008–2009.
Assessment of association between use of SP in
pregnancy and mutations in SP drug resistance genes
Since the increased prevalence in drug resistance molecu-
lar markers paralleled the increased use of SP during preg-
nancy as observed in Figure 3, the association between SP
use in pregnancy and its effect on drug resistance molecu-
lar markers was further assessed. For the 1996–2000 study
only, the unadjusted odds of having the dhps double mu-
tant genotype among women who used SP was 3.5 [95 %
CI, 1.3 to 9.6] times greater than the odds of women who
did not use SP (Table 3). More mutations in the combined
dhfr/dhps genotype were also associated with SP use dur-
ing this study period (unadjusted OR, 4.2 [95 % CI, 1.6 to
10.9]). However, after adjusting for all other explanatory
variables, neither association remained significant in multi-
variable analysis (Table 3). No other significant associationsbetween the use of SP in pregnancy and mutations in dhfr,
dhps and the combined dhfr/dhps genotypes were observed
in the 2002–2008 and 2008–2009 study periods.
Prevalence of mixed infection and mean MOI over time
Previous studies suggest that transmission intensity or
transmission reduction by ITNs could be one of factors
that influence the prevalence of parasite drug resistance
molecular markers [49,50]. In order to estimate the
change in transmission intensity during the study period
and the possible effect of transmission reduction by ITN
intervention on the parasite populations, the prevalence
of mixed infection and MOI were measured by using size
variant alleles of msp2. Figure 4 shows that the preva-
lence of mixed infections decreased from 67.5 % in
1996–1998 to 18 % in 2009, although the highest preva-
lence of mixed infections was observed from 2004 to
2007 (87.1 % to 89.1 %, respectively) (P< 0.001). Like-
wise, the mean MOI also decreased significantly from
2.08 ± 0.96 to 1.00 ± 0.61 between 1996–1998 and 2009
Figure 2 Temporal trends of SP drug resistant genotypes from 1996 to 2009 by study period. A, dhfr genotypes. B, dhps genotypes.
C, combined dhfr/dhps genotypes.
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was detected between 2004 and 2007 period (Figure 4)
(P< 0.001).
Discussion
Anti-malarial drug resistance to SP, a factor contributing
to diminishing therapeutic efficacy, is increasing in many
malaria endemic countries. All African countries have
already replaced SP with artemisinin-based combination
therapy as the first line treatment for uncomplicated
malaria, according to the WHO guidelines. However,
SP remains the recommended drug for IPTp in malaria
endemic areas. In this study, the temporal trends of SP
resistance molecular markers in the parasites fromKenyan pregnant women and potential epidemiological
factors affecting the prevalence of the resistant markers
in the pregnant women were evaluated.
The key observations from this study were: 1) a notice-
able background level of SP mutations in pregnant women
prior to IPTp policy adoption, 2) a significant rise in the
prevalence of the drug resistance markers after IPTp adop-
tion seemingly in parallel with an increase in the percent-
age of SP use in pregnancy, and 3) however an association
between more SNP mutations and SP use during preg-
nancy only in the 1996–2000 study in univariable analysis
but not in 2002–2008 and 2008–2009 study periods.
These results suggest that the increase in drug-resistant
parasites in the pregnant women over time could be
Figure 3 Prevalence of dhfr triple mutant, dhps double mutant and the combined dhfr/dhps quintuple genotype before and after IPTp
policy adoption. Years with fewer than 25 samples were merged with either the previous year or after, depending on the number of samples in
that particular year. The bars represent 95 % CI. No samples were collected in 2001 and therefore data for this year was not presented. For 1996–2000
and 2002–2008 periods, only history of SP use (case management or any dose of IPTp-SP) in pregnancy was documented while IPTp use was recorded
for 2008–2009.
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role of IPTp adoption and SP use in pregnancy. Firstly,
compared to high drug pressure in large general popula-
tion (children and adults) due to SP use for case manage-
ment, drug pressure in the small minority of pregnant
women by IPTp-SP use is relatively lower. It is most likely
that the resistant parasites selected by the use of SP for
case management in the large general population could
serve as the potential infectious reservoirs for pregnant
women, thus high prevalence of drug resistant parasites
circulated in the large non-pregnant population couldcontribute to the observed temporal increase in resistance
markers in pregnant women. Indeed, the results from our
previous study, conducted in the general population of the
same area, showed that the prevalence of dhfr/dhps quin-
tuple mutant parasites in children from the same study
area increased from 29 % in 1996 to 62 % and 85 % in
2001 and 2007, respectively, after the drug policy change
to SP for the treatment of uncomplicated malaria in 1998
[41]. Secondly, IPTp-SP works by intermittently clearing
asymptomatic parasitaemia and preventing new infections
in pregnant women [51] and the decreasing prevalence
Table 2 Temporal trends of additional dhps combinations from 1996 to 2009 by study period
dhps combinations 1996-2000(%) 2002-2008(%) 2008-2009(%) P value
S436A/F/H+A437G+K540E
Wild type 44.4 1.7 0
Single mutant 25.6 1.7 0.8 <0.001
Double mutant 30.0 94.3 93.2
Triple mutant 0 2.3 6.0
A437G+K540E+A581G
Wild type 56.1 2.3 0
Single mutant 13.9 1.1 0.8 <0.001
Double mutant 30.0 96.6 93.9
Triple mutant 0 0 5.3
S436A/F/H+A437G+K540E+A581G
Wild type 44.4 1.7 0
Single mutant 25.6 1.7 0.8 <0.001
Double mutant 30.0 94.3 88.5
Triple mutant 0 2.3 9.9
Quadruple 0 0 0.8
P values derived from exact Pearson chi-square test. Mutated amino acids are depicted in bold font.
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http://www.malariajournal.com/content/11/1/134and intensity of infection in subsequent pregnancies also
indicates the acquired immunity of the pregnant woman
in preventing malaria infection as well as clearance of
parasites [52]. Recent studies from several African coun-
tries reported increased prevalence of mutant genotypes
due to IPTp-SP [33,53,54], but the increased resistant
parasites did not affect the protective efficacy of IPTp
[53,54]. Based on the results from others [53,54] and the
molecular data from this study, the authors speculate thatTable 3 Univariable and multivariable analyses of the associa
genotypes by study period
Outcome 1996-2000 20
Unadjusted Adjustede U
OR (95 % CI) OR (95 % CI) O
dhfr triple mutanta
Use of SP in pregnancy{ 2.7 (1.0 to 7.5) 2.4 (0.8 to 7.1) 1.
dhps double mutantb
Use of SP in pregnancy 3.5 (1.3 to 9.6)* 2.3 (0.7 to 7.0) 1.
Combined dhfr/dhps c,d
Use of SP in pregnancy 4.2 (1.6 to 10.9) * 2.6 (0.9 to 7.4) 1.
Note: OR, odds ratio; CI, confidence interval.
{For 1996–2000 and 2002–2008 studies, only history of SP use (case management o
recorded for 2008–2009.
adhfr triple mutant was compared to the grouped all other dhfr genotypes using bin
bdhps double mutant was compared to the grouped all other dhps genotypes using
c For 1996–2000, combined dhfr/dhps mutations were analysed using three categor
group, (2) quadruple mutant, and (3) quintuple mutant.
d For 2002–2008 and 2008–2009, quintuple combined dhfr/dhps mutant was compa
logistic regression.
e Adjusted ORs are derived from multivariable binary or cumulative logistic regressi
status, sample collection year, and total number of msp2 clones.
f Only one sample was single mutant in 2008–2009, while the rest were double mu
* Statistically significant, P< 0.05.the interplay between IPTp-SP and host immunity in preg-
nant women could also play a role in the selection of drug
resistant parasites, consequently shaping the parasite drug
resistant profile in pregnant women. However, further
studies are required to test this hypothesis. Lastly, the use
of CTX as prophylaxis against opportunistic infection in
HIV infected pregnant women, particularly the validated
CTX use in the third study (2008–2009), might also con-
tribute to the increased prevalence of SP drug resistanttion between SP use and mutations in SP drug resistance
02-2008 2008-2009
nadjusted Adjustede Unadjusted Adjustede
R (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
4 (0.634 to 3.0) 1.4 (0.6 to 3.2) 1.1 (0.3 to 3.3) 1.3 (0.4 to 4.7)
2 (0.3 to 4.1) 1.3 (0.3 to 5.2) - f - f
3 (0.6 to 2.6) 1.4 (0.7 to 2.9) 1.0 (0.3 to 2.9) 1.2 (0.3 to 4.1)
r any dose of IPTp) in pregnancy was documented while IPTp use was
ary logistic regression.
binary logistic regression.
ies in cumulative logistic regression: (1) grouping all other genotypes as one
red to the grouped all other combined dhfr/dhps genotypes using binary
on, controlling for gravidity, log transformed peripheral parasite density, HIV
tant, therefore association analysis was not performed.
Figure 4 Prevalence of mixed infection and mean MOI over time. Years with fewer than 25 samples were merged with either the previous
year or after, depending on the number of samples in that particular year. No samples were collected in 2001 and therefore data for this year was
not presented. The bars represent 95 % CI while mean MOI error bars represent SD. For 1996–2000 and 2002–2008 periods, only history of SP use
(case management or any dose of IPTp-SP) in pregnancy was documented while IPTp use was recorded for 2008–2009.
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http://www.malariajournal.com/content/11/1/134genotypes over time, possibly due to cross resistance be-
tween trimethoprim and pyrimethamine in P. falciparum
malaria parasites [18]. Since multiple factors could be
involved in the selection of resistant parasites in pregnant
women, molecular markers when used alone may not ac-
curately predict the failure of IPTp-SP. The assessment of
the linkage between SP drug resistance molecular markers
and efficacy of IPTp-SP in pregnant women in different
malaria endemic areas becomes extremely important.
This study also detected 5.3 % of the dhps triple mutant
(A437G/K540E/A581G) (7 samples), the presence of quad-
ruple dhps mutant (S436A/F/H+A437G+K540E+A581G)
(1 sample), the dhfr 164 (I164L) mutation (1 sample), and
an increase in the new mutation at dhps S436H (5 samples)
in the third study period (2008–2009). These results suggest
progressive expansion of new mutations or new genotypes
in parasite populations in Kenya. Although the contribution
of the new mutation dhps S436H (unreported prior to this
study) to drug resistance is unclear, the mutations at dhfr
164 and dhps 581 or related genotypes have been associated
with a high-level of SP resistance mainly in Southeast Asia
and South America [55,56] and, more recently, have been
reported on the African continent [26,57-60]. Due to the
small sample size in the new drug resistant genotype/SNP
group, no further association analyses were conducted.
However, higher placental parasite density in 2008–2009
period was observed as compared to the 1996–2000. It is
possible that the progressive expansion of the new geno-
types could be related to the overgrowth of resistant para-
sites, i.e. the highly resistant parasites out-compete less fitparasites [61-63]. Recent data from Tanzania suggest that
the emergence of the dhps triple mutant (A437G/K540E/
A581G) associated with the IPTp-SP use in pregnant
women led to high-density parasitaemia [33]. Taken to-
gether, the emergence of new genotypes containing muta-
tions in dhps 436 and dhps 581, coupled with the presence
of dhfr 164 mutation in pregnant women may present a
challenge for the future usefulness of IPTp-SP intervention
in Kenya.
A recent study conducted in Mozambique reported
that IPTp-SP use increased the prevalence of resistance
markers in HIV positive women and mutant infections
were more prevalent in placental than peripheral samples
[36]. However, in this investigation, no statistical differ-
ences were found in the prevalence of dhps triple, dhps
double and dhfr/dhps combined quintuple mutants be-
tween HIV positive and HIV negative women during all
the three study periods. In the current study, there was
also no significant difference in the prevalence of SP re-
sistance markers and mean MOI between peripheral and
placental-paired samples in the third study period when
SP resistance was high. The discrepancy of the results
between these two studies could be due to the differences
in the study design, level of existing SP pressure and resist-
ance, HIV care and other unknown factors. The Mozam-
bique study used samples from a randomized double-
blind, placebo-control trial of IPTp-SP conducted before
IPTp-SP policy adoption, while the current study employed
the samples collected from three different observational
studies before and after IPTp-SP adoption for an extended
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http://www.malariajournal.com/content/11/1/134period. However, the observation of no significant differ-
ences in mutant infections between placental and peripheral
samples in the current study is consistent with the results
from the studies conducted in Tanzania and Ghana, the
countries with relative high levels of SP resistance [33,64].
This suggests that either peripheral or placental samples
can be used for monitoring drug resistant molecular mar-
kers in areas with high SP resistance level.
Overall, the prevalence of mixed infection and mean
MOI decreased significantly between 1996 and 2009, but
the highest parasite diversity was observed between the
2004 and 2007 period. The observed sharp increase in
parasite diversity from 2004 could reflect the higher
transmission intensity of the study site as the second
malaria in pregnancy study was conducted from 2004 in
the rural area (Siaya) where malaria transmission is rela-
tively higher compared to Kisumu town. However, the
drop in parasite diversity in 2008 followed by a signifi-
cant decrease in 2009 might be related to the combin-
ation of transmission reduction by the implementation
of free distribution of ITNs to pregnant women in ANC
from early 2008 and SP use in pregnancy. The diversity
of P. falciparum malaria reflects acquisition of new infec-
tions and is associated with transmission intensity [65].
A previous study conducted in Tanzania also showed
that parasite diversity measured by msp2 was reduced in
women with recent IPTp-SP use [33]. Nevertheless, the
observation, overall decreased parasite diversity in con-
junction with increased prevalence of drug resistance
molecular markers over time in this study, suggests that
intra-host removal of SP drug sensitive parasite clones is
present, thus purifying drug resistant parasites in preg-
nant women.
There were few limitations to the current study. First,
the present study utilized data from three different mal-
aria in pregnancy observational studies and these three
studies varied in their original study designs. Therefore,
there were some differences in patient recruitment and
procedures of clinical data collection, including assess-
ment of IPTp use and use of SP for case management,
which could have affected the statistical association ana-
lysis. Additionally, the lack of baseline samples from
women prior to IPTp administration and absence of in-
formation for early versus later IPTp-SP or SP use before
delivery limited the comparisons to assess the selection
of drug resistant parasites in pregnant women whose im-
munity and pharmacokinetics are altered during preg-
nancy. Another limitation to the current study was the
lack of samples from non-pregnant women as controls
from the same study periods due to original design of
the three previous observational studies. It will be ideal
to conduct a well-controlled longitudinal IPTp drug re-
sistance studies in both pregnant and non-pregnant
women of the same population over a period of time.Such studies will help to examine the selection of drug
resistant parasites and evaluate the potential factors
involved in the development of SP resistance in pregnant
women.Conclusions
There was a significant increase in dhfr/dhps quintuple
mutant and the emergence of new genotype containing
dhps 581 and dhps S436H in the parasites from pregnant
women in western Kenya over 13 years. IPTp adoption
and SP use in pregnancy only played a minor role in the
increased drug-resistant parasites in the pregnant women
over time. Most likely, the high prevalence of resistant
parasites selected by the use of SP for case management
in large non-pregnant population in the same study area,
CTX use, host immunity and transmission intensity might
have contributed to the temporally increased prevalence of
SP resistant parasites in pregnant women. Further investi-
gations in the region to determine the linkage between SP
drug resistance molecular markers and efficacy of IPTp-SP
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